|
Vertigo
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Women and CYP3A5*1/*1 subjects showed more often dizziness (p = 0.034; p = 0.009).
|
29325225 |
2018 |
|
Venous Thromboembolism
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
The objective was to investigate the impact of CYP3A5 and CYP1A2 genetic polymorphisms on the association of VTE with hormone therapy.
|
18628519 |
2008 |
|
Ulcerative Colitis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus.
|
24033383 |
2014 |
|
Ulcerative Colitis
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, in order to evaluate UC-specific components in UC mouse serum, we analyzed the influence of serum derived from UC mice on the results of fluorescent P450 inhibition assays based on 12 human P450 enzymes, such as CYP1A1, CYP2C8, CYP2E1,CYP3A4, CYP1A2, CYP2D6, CYP2A13, CYP2B6, CYP2C9, CYP2C18, CYP2C19, and CYP3A5.
|
29842871 |
2018 |
|
Ulcerative Colitis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Because Tac response in patients who have undergone solid-organ transplantation has been associated with the presence of variants in CYP3A and ABCB1, we elucidated the contributions of CYP3A4*1B and CYP3A5*3 and of ABCB1 1236C>T, 2677G>T,A, and 3435C>T polymorphisms to Tac response in 89 patients with UC.
|
21289623 |
2011 |
|
Ulcerative Colitis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We investigated the correlation between CYP3A5 genetic polymorphisms and the adverse events in patients with UC.
|
27717793 |
2017 |
|
Tumor Cell Invasion
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Mechanistic investigations showed that CYP3A5 overexpression limited MMP2/9 function and suppressed HCC migration and invasion in vitro and in vivo by inhibiting AKT signaling.
|
25649767 |
2015 |
|
Tuberculosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The data suggested that CYP2C19 and CYP3A5 polymorphisms affect susceptibility to paediatric TB.
|
22771593 |
2012 |
|
Tuberculosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to examine the effect of two gene polymorphisms, one in the CYP2B6 (rs3745274) gene and one in the CYP3A5 (rs776746) gene, on the development of hepatotoxicity in patients treated with anti-TB drugs in a Brazilian Amazon population.
|
25271170 |
2015 |
|
Toxic Encephalitis
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
|
21225912 |
2011 |
|
Thrombus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
|
16754899 |
2006 |
|
Thrombosis
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.
|
16754899 |
2006 |
|
Therapy-related acute myeloid leukemia and myelodysplastic syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Our data do not support an association between common CYP3A4, NQO1 or CYP3A5 polymorphisms and the risk of t-ML in children treated for ALL.
|
12439220 |
2002 |
|
Tardive Dyskinesia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.
|
16160620 |
2005 |
|
Streptozotocin Diabetes
|
0.200 |
Biomarker
|
disease |
CTD_mouse |
Modulations of cytochrome P450 expression in diabetic mice by berberine.
|
22342832 |
2012 |
|
stage, prostate cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The CYP3A5 A6986G polymorphism may be specifically associated with a decreased risk of low-grade or early stage prostate cancer.
|
15876487 |
2005 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
However, six individual genes (including SULT2B1, CYP1B1, CYP3A7, CYP3A5, SHBG and CYP11A1) were significantly associated with ESCC risk (P < 0.05).
|
23358850 |
2013 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
mRNA expression of CYP2E1, CYP2C, CYP3A4, and CYP3A5 was determined using RT-PCR in both normal and malignant esophageal tissues of patients with untreated esophageal SCC (n = 21) and in controls (n = 10).
|
17373732 |
2007 |
|
Squamous cell carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Gene-environment interaction: the role of SULT1A1 and CYP3A5 polymorphisms as risk modifiers for squamous cell carcinoma of the oesophagus.
|
16272171 |
2006 |
|
Squamous cell carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
CYP2C8, CYP3A4, CYP3A5, and CYP2E1) between SCC patients and healthy subjects and may contribute to the development of SCC in the esophagus.
|
17373732 |
2007 |
|
Solid Neoplasm
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Recently, it was published that CYP3A5 contributes to chemotherapeutic drug resistance in a wide range of solid tumors, including hepatocellular carcinoma.
|
31588878 |
2019 |
|
Small cell carcinoma of lung
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Certain combined CYP3A4/CYP3A5 haplotypes show differential susceptibility to prostate cancer and there is a nonsignificant increase in the risk of small-cell lung cancer for a CYP3A5*1/*1 genotype.
|
16430309 |
2006 |
|
Sleep Apnea, Central
|
0.010 |
Biomarker
|
disease |
BEFREE |
CYP3A5 genotyping is a new approach to detecting FK506 dose requirement and a predictive index for the FK506 or CsA treatment selection in kidney recipients.
|
29113387 |
2017 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
In this study, we investigated whether single nucleotide polymorphisms (SNPs) identified by genome-wide association study (GWAS) (MAP3K1, FGFR2, TNRC9, HCN1, and 5p12), and SNPs involved in the metabolism of estrogen (CYP19, COMT, ESR1, and UGT1A1), tamoxifen (CYP2C9, CYP2C19, CYP3A5, and CYP2D6), and chemotherapeutic agents (ABCB1, ALDH3A1, and CYP2B6) are associated with the prognoses of 414 hormone receptor (HR)-positive early breast cancers with negative or 1 to 3 nodal metastases.
|
28178648 |
2017 |
|
Secondary malignant neoplasm of colon and/or rectum
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYP3A5 rs776746 A>G polymorphisms have a prognostic contribution toward FOLFIRI regimen in mCRC.
|
25934339 |
2015 |